Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)

NCT03891784 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03891784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2019
Completion date
July 31, 2026
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced digestive system neuroendocrine neoplasm, digestive system neuroendocrine tumor, foregut neuroendocrine tumor, hindgut neuroendocrine tumor, locally advanced unresectable digestive system neuroendocrine neoplasm, metastatic digestive system neuroendocrine neoplasm, midgut neuroendocrine tumor, pancreatic neuroendocrine tumor, refractory digestive system neuroendocrine neoplasm